You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31
|
---|---|
Published in |
Journal of Clinical Oncology, March 2015
|
DOI | 10.1200/jco.2014.56.9590 |
Pubmed ID | |
Authors |
Karen A Gelmon, Frances M Boyle, Bella Kaufman, David G Huntsman, Alexey Manikhas, Angelo Di Leo, Miguel Martin, Lee S Schwartzberg, Julie Lemieux, Samuel Aparicio, Lois E Shepherd, Susan Dent, Susan L Ellard, Katia Tonkin, Kathleen I Pritchard, Timothy J Whelan, Dora Nomikos, Arnd Nusch, Robert E Coleman, Hirofumi Mukai, Sergei Tjulandin, Rustem Khasanov, Shulamith Rizel, Anne P Connor, Sergio L Santillana, Judith-Anne W Chapman, Wendy R Parulekar |
X Demographics
The data shown below were collected from the profiles of 33 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 10 | 30% |
Spain | 6 | 18% |
United Kingdom | 2 | 6% |
Germany | 1 | 3% |
Japan | 1 | 3% |
Canada | 1 | 3% |
Turkey | 1 | 3% |
Gibraltar | 1 | 3% |
Unknown | 10 | 30% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 18 | 55% |
Practitioners (doctors, other healthcare professionals) | 9 | 27% |
Science communicators (journalists, bloggers, editors) | 3 | 9% |
Scientists | 3 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 225 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 1 | <1% |
France | 1 | <1% |
Ecuador | 1 | <1% |
Brazil | 1 | <1% |
United Kingdom | 1 | <1% |
Spain | 1 | <1% |
Unknown | 219 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 35 | 16% |
Other | 32 | 14% |
Student > Master | 32 | 14% |
Student > Ph. D. Student | 25 | 11% |
Student > Bachelor | 20 | 9% |
Other | 33 | 15% |
Unknown | 48 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 85 | 38% |
Pharmacology, Toxicology and Pharmaceutical Science | 20 | 9% |
Biochemistry, Genetics and Molecular Biology | 16 | 7% |
Agricultural and Biological Sciences | 16 | 7% |
Nursing and Health Professions | 7 | 3% |
Other | 25 | 11% |
Unknown | 56 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 47. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 April 2018.
All research outputs
#909,576
of 25,837,817 outputs
Outputs from Journal of Clinical Oncology
#2,163
of 22,362 outputs
Outputs of similar age
#11,335
of 279,563 outputs
Outputs of similar age from Journal of Clinical Oncology
#31
of 219 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,362 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.1. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,563 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 219 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.